Korea Research Institute of Bioscience and Biotechnology

Enzychem Lifesciences Corporation

Tae Suk Lee

Kyung Seop Ahn

Jae Wha Kim

Ki-Young Sohn

Ho Bum Kang

Jong Koo Kang

Sei Ryang Oh

Yong-Hae Han

Myung Hwan Kim

Jae Min Shin

Young Eun Ko

Sei-Ryang Oh

Young Sik Jung

Beom Su Park

The present invention relates to a composition containing a monoacetyldiglyceride compound as an active ingredient, for inhibiting blood cancer or metastasis, and a use thereof. The monoacetyldiglyceride compound according to the present invention has excellent effects of inhibiting the expression of IL-4 and inhibiting the activity of STAT-6, and thereby is capable of overcoming side effects of currently used blood cancer or metastasis inhibiting agents. Also, the monoacetyldiglyceride compound is a non-toxic compound having superior therapeutic effects and thus can be useful as a composition for preventing, treating, or improving blood cancer and metastasis.

Composition containing monoacetyldiacylglycerol compound as active ingredient for inhibiting blood cancer or metastasis

The invention relates to pharmaceutical compositions, as well as health functional food compositions and quasi-drug compositions, for preventing, treating, or improving rheumatoid arthritis, comprising a monoacetyldiacylglycerol compound as an active ingredient. The monoacetyldiacylglycerol of the invention is effective in inhibiting the phosphorylation of STAT-3 known to be a therapeutic target for rheumatoid arthritis. As the monoacetyldiacylglycerol is an effective therapeutic agent without toxicity, the monoacetyldiacylglycerol can overcome the side effects of the medicines currently used in the treatment of rheumatoid arthritis. Thus, the monoacetyldiacylglycerol can be used for preventing, treating or improving rheumatoid arthritis.

Compositions containing monoacetyldiacylglycerol compound as an active ingredient for preventing or treating rheumatoid arthritis

Growing community of inventors

Daejeon, South Korea

Tae Suk Lee